ALS drug from Google-backed anti-aging company Calico fails clinical test
Age is an issue of mind over matter — h/t Mark Twain — but early ALS clinical trial results from Google-backed aging-disease ...
Google's anti-aging company just released 'disappointing' drug trial results
Google’s ( GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug.
Pharmaceutical Technology6d
Fosigotifator by Calico Life Sciences for Unspecified Central Nervous System Disorders: Likelihood of Approval
Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.
newsbytesapp.com4d
ALS drug by Google's anti-aging subsidiary fails clinical trial
Calico, Google's anti-aging subsidiary, has announced disappointing results from its first-ever drug trial. The experimental ...
STAT5d
Google’s secretive anti-aging company Calico finally released data. Its drug failed
The company said Monday that fosigotifator failed to outperform placebo in slowing the neurodegenerative disease, but is ...
FierceBiotech5d
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests, denting hopes for shared mechanism
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
Becker's Hospital Review5d
Google's ALS drug fails phase 3 trial
A clinical trial evaluating the drug fosigotifator in patients with amyotrophic lateral sclerosis has failed to meet its primary endpoint, according to topline results from the Healey ALS platform ...